IMPACT trial is evaluating the safety and efficacy of pemvidutide in approximately 190 subjects with MASH; top-line efficacy data expected in Q2 2025

Register to unlock this article

Register to read this story and more for free.

Signing up for an account helps us improve your browsing experience.

Continue

OR

See our subscription options.

Already have an account? Log in here